LLY vs. NVO
Compare and contrast key facts about Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: LLY or NVO.
Correlation
The correlation between LLY and NVO is 0.32, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
LLY vs. NVO - Performance Comparison
Loading data...
Key characteristics
LLY:
-0.02
NVO:
-1.17
LLY:
0.17
NVO:
-1.66
LLY:
1.02
NVO:
0.79
LLY:
-0.11
NVO:
-0.81
LLY:
-0.21
NVO:
-1.50
LLY:
12.60%
NVO:
32.04%
LLY:
38.10%
NVO:
42.60%
LLY:
-68.27%
NVO:
-71.29%
LLY:
-22.02%
NVO:
-54.60%
Fundamentals
LLY:
$678.30B
NVO:
$295.20B
LLY:
$12.27
NVO:
$3.53
LLY:
61.58
NVO:
19.19
LLY:
1.16
NVO:
1.02
LLY:
13.84
NVO:
0.97
LLY:
44.23
NVO:
14.44
LLY:
$49.00B
NVO:
$303.14B
LLY:
$40.03B
NVO:
$255.65B
LLY:
$16.67B
NVO:
$154.08B
Returns By Period
In the year-to-date period, LLY achieves a -3.19% return, which is significantly higher than NVO's -22.75% return. Over the past 10 years, LLY has outperformed NVO with an annualized return of 28.54%, while NVO has yielded a comparatively lower 10.94% annualized return.
LLY
-3.19%
1.86%
-8.58%
-0.90%
38.06%
28.54%
NVO
-22.75%
1.04%
-37.93%
-49.62%
17.24%
10.94%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
LLY vs. NVO — Risk-Adjusted Performance Rank
LLY
NVO
LLY vs. NVO - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Eli Lilly and Company (LLY) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
LLY vs. NVO - Dividend Comparison
LLY's dividend yield for the trailing twelve months is around 0.72%, less than NVO's 2.46% yield.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
LLY Eli Lilly and Company | 0.72% | 0.67% | 0.78% | 1.07% | 1.23% | 1.75% | 1.96% | 1.94% | 2.46% | 2.77% | 2.37% | 2.84% |
NVO Novo Nordisk A/S | 2.46% | 1.68% | 1.00% | 1.20% | 1.34% | 1.86% | 2.14% | 2.47% | 2.12% | 3.93% | 1.31% | 1.96% |
Drawdowns
LLY vs. NVO - Drawdown Comparison
The maximum LLY drawdown since its inception was -68.27%, roughly equal to the maximum NVO drawdown of -71.29%. Use the drawdown chart below to compare losses from any high point for LLY and NVO. For additional features, visit the drawdowns tool.
Loading data...
Volatility
LLY vs. NVO - Volatility Comparison
Eli Lilly and Company (LLY) has a higher volatility of 21.88% compared to Novo Nordisk A/S (NVO) at 14.82%. This indicates that LLY's price experiences larger fluctuations and is considered to be riskier than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
LLY vs. NVO - Financials Comparison
This section allows you to compare key financial metrics between Eli Lilly and Company and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LLY vs. NVO - Profitability Comparison
LLY - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a gross profit of 10.50B and revenue of 12.73B. Therefore, the gross margin over that period was 82.5%.
NVO - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a gross profit of 65.20B and revenue of 78.09B. Therefore, the gross margin over that period was 83.5%.
LLY - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported an operating income of 5.41B and revenue of 12.73B, resulting in an operating margin of 42.5%.
NVO - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported an operating income of 38.79B and revenue of 78.09B, resulting in an operating margin of 49.7%.
LLY - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Eli Lilly and Company reported a net income of 2.76B and revenue of 12.73B, resulting in a net margin of 21.7%.
NVO - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Novo Nordisk A/S reported a net income of 29.03B and revenue of 78.09B, resulting in a net margin of 37.2%.